The stock of Elevation Oncology Inc (ELEV) has seen a 9.29% increase in the past week, with a 0.51% gain in the past month, and a 25.80% flourish in the past quarter. The volatility ratio for the week is 18.87%, and the volatility levels for the past 30 days are at 12.90% for ELEV. The simple moving average for the past 20 days is 0.41% for ELEV’s stock, with a -66.59% simple moving average for the past 200 days.
Is It Worth Investing in Elevation Oncology Inc (NASDAQ: ELEV) Right Now?
The 36-month beta value for ELEV is also noteworthy at 1.28. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ELEV is 52.02M, and at present, short sellers hold a 12.39% of that float. The average trading volume of ELEV on January 13, 2025 was 1.01M shares.
ELEV) stock’s latest price update
The stock price of Elevation Oncology Inc (NASDAQ: ELEV) has dropped by -13.72 compared to previous close of 0.75. Despite this, the company has seen a gain of 9.29% in its stock price over the last five trading days. prnewswire.com reported 2024-12-12 that — EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload – — Following recently signed global license agreement with Synaffix, EO-1022 leverages the company’s GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin E™ linker-payload — – Elevation Oncology expects to present EO-1022 preclinical data in 1H 2025 and to file an IND application in 2026 – BOSTON, Dec. 12, 2024 /PRNewswire/ — Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the nomination of EO-1022 as its HER3 ADC development candidate. EO-1022 is currently progressing through preclinical development, and Elevation Oncology expects to file an investigational new drug (IND) application in 2026.
Analysts’ Opinion of ELEV
Piper Sandler, on the other hand, stated in their research note that they expect to see ELEV reach a price target of $10. The rating they have provided for ELEV stocks is “Overweight” according to the report published on May 31st, 2024.
Stephens gave a rating of “Overweight” to ELEV, setting the target price at $8 in the report published on May 14th of the previous year.
ELEV Trading at 5.00% from the 50-Day Moving Average
After a stumble in the market that brought ELEV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.84% of loss for the given period.
Volatility was left at 12.90%, however, over the last 30 days, the volatility rate increased by 18.87%, as shares sank -12.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.18% upper at present.
During the last 5 trading sessions, ELEV rose by +9.29%, which changed the moving average for the period of 200-days by -85.80% in comparison to the 20-day moving average, which settled at $0.6480. In addition, Elevation Oncology Inc saw 15.61% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ELEV
Current profitability levels for the company are sitting at:
- -724.26 for the present operating margin
- 0.5 for the gross margin
The net margin for Elevation Oncology Inc stands at -723.24. The total capital return value is set at -0.42. Equity return is now at value -63.67, with -40.67 for asset returns.
Based on Elevation Oncology Inc (ELEV), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -1.24. The debt to equity ratio resting at 0.45. The interest coverage ratio of the stock is -8.76.
Currently, EBITDA for the company is -41.47 million with net debt to EBITDA at 0.41. When we switch over and look at the enterprise to sales, we see a ratio of 366.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.77.
Conclusion
In summary, Elevation Oncology Inc (ELEV) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
